Göran Tornling
Director/Board Member at ACUCORT AB
Profile
Göran Tornling is currently an Independent Director at AcuCort AB, an Associate Professor at Karolinska Institutet, the Chief Medical Officer & Vice President at Biolipox AB, the Chief Medical Officer at AnaMar AB, and the Chief Medical Officer at Gesynta Pharma AB.
He previously worked as a Director-Medical Science at AstraZeneca R&D Boston, Inc. Dr. Tornling holds a doctorate degree from Karolinska Institutet.
Göran Tornling active positions
Companies | Position | Start |
---|---|---|
ACUCORT AB | Director/Board Member | 2020-12-31 |
Biolipox AB
Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Chief Tech/Sci/R&D Officer | 2006-08-31 |
Karolinska Institutet | Corporate Officer/Principal | - |
Gesynta Pharma AB
Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Chief Tech/Sci/R&D Officer | - |
AnaMar AB
AnaMar AB Pharmaceuticals: MajorHealth Technology AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden. | Chief Tech/Sci/R&D Officer | - |
Former positions of Göran Tornling
Companies | Position | End |
---|---|---|
AstraZeneca R&D Boston, Inc.
AstraZeneca R&D Boston, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca R&D Boston, Inc. develops, manufactures and markets prescription pharmaceutical drugs. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Training of Göran Tornling
Karolinska Institutet | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ACUCORT AB | Health Technology |
Private companies | 4 |
---|---|
Biolipox AB
Biolipox AB Pharmaceuticals: MajorHealth Technology Biolipox AB develops and manufactures pharmaceuticals products. The company engages in the research and development of pharmaceuticals for the treatment of respiratory and other inflammatory diseases such as asthma, chronic obstructive pulmonary disease, rhinitis, pain, and arthritis. It was founded in June 2000 and is headquartered in Solna, Sweden. | Health Technology |
AstraZeneca R&D Boston, Inc.
AstraZeneca R&D Boston, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca R&D Boston, Inc. develops, manufactures and markets prescription pharmaceutical drugs. The company is headquartered in Cambridge, MA. | Health Technology |
Gesynta Pharma AB
Gesynta Pharma AB Pharmaceuticals: MajorHealth Technology Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden. | Health Technology |
AnaMar AB
AnaMar AB Pharmaceuticals: MajorHealth Technology AnaMar AB develops drugs and provides research services for chronic joint diseases. It focuses on the discovery, development and commercialization of novel therapeutic strategies to treat debilitating inflammation and pain. The company was founded in 1998 and is headquartered in Lund, Sweden. | Health Technology |
- Stock Market
- Insiders
- Göran Tornling